A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
New research labs and process development services to enable next generation therapeutics
Construction will begin this year with the new capacity anticipated by 2025
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
Subscribe To Our Newsletter & Stay Updated
